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ABSTRACT
THE EFFECTS OF VARYING CONCENTRATION AND DURATION OF CFC-113
EXPOSURE ON END-EXHALED BREATH CFC-113 CONCENTRATIONS
by Demetra G. Dalamagas
Subjects were exposed to different concentrations of CFC-113 for variable duration while
conducting 30-minute exercise regiments. End-exhaled breath samples were collected 25, 30 and
35 minutes after the exercise regiment and quantified using gas chromatography. Three
comparative studies were conducted.
A short duration administration delivered at the beginning or at the end of the regiment
was compared to a long duration administration delivered at the beginning or at the end of the
exercise regiment. The second study compared breath samples when 500 ppm of CFC-113 was
administered at the beginning or end six minutes of the regiment. The third compared continuous
exposures (30 min of 100 ppm) to intermittent exposures (three intermittent 2-min exposures of
500 ppm). This study determined that equivalent doses of CFC-113 administered with variable
exposure profiles to human subjects produced statistically equivalent end-exhaled CFC-113
concentration, except in two cases.
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List of Abbreviations
ECD = Electron Capture Device; Type of detector fitted to the Gas Chromatograph.
GC = Gas Chromatograph
LB = Long, Beginning Scenario; A long exposure (15.15 minutes of 33 ppm of CFC)
administered at the beginning of the 30 minute exercise regiment.
LE = Long, End Scenario; A long exposure (15.15 minutes of 33 ppm of CFC) administered
at the end of the 30 minute exercise regiment.
SB = Short, Beginning Scenario; A short exposure (1 minute of 500 ppm of CFC)
administered at the beginning of the 30 minute exercise regiment.
SE = Short, End Scenario; A short exposure (1 minute of 500 ppm of CFC) administered at
the end of the 30 minute exercise regiment.
END = End Scenario; A six minute exposure of 500 ppm CFC administered at the end of the
exercise regiment.
BEG = Beginning Scenario; A six minute exposure of 500 ppm CFC administered at the
beginning of the exercise regiment.
CON = Continuous Scenario; A continuous exposure of 100 ppm CFC administered throughout
the exercise regiment.
INT = Intermittent Scenario; An intermittent exposure of 500 ppm CFC administered in 2-
minute intervals, three times during the exercise regiment.
SD =  Standard Deviation; Let X be a random variable with probability distribution f(x) and
mean  µ. The variance of X is σ2=∑x(x−µ)2 f(x), if X is continuous. The positive square
root of the variance,σ , is called the standard deviation of X (Walpole et. al. , 1998).
CV = Coefficient of Variation; CV = SD/ µ. x 100
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Introduction
Experiment Rationale and Design
Coffey et. al. are in the process of correlating fit factors acquired from quantitative fit
testing to actual exposure by utilizing CFC-113 (chlorofluorocarbon-113, Freon-113, or 1,1,2-
trichloro-1,2,2-trifluoroethane) as a biomarker  to measure exposure in air purifying respirators
(Coffey et. al., 1998; Coffey et. al., 1998; Coffey, 1997).  The subject’s actual exposure is
determined by measuring the amount of CFC-113 in the exhaled breath after they perform a
standardized exercise regiment while in a chamber containing CFC-113.  Presence of CFC-113
in the exhaled breath represents evidence of respirator leaks and allow the investigators to
correlate actual exposure to quantitative respirator fit factors. This thesis was conducted to
determine if different exposure scenarios affected end-exhaled CFC-113 concentrations.
This study questions whether equivalent doses (in ppm-min) of CFC-113 administered
with variable exposure profiles to human subjects produced statistically equivalent end-exhaled
air CFC-113 concentration.  That is, if the different exposure scenarios of our study represent
different ways in which leaks might occur during respirator tests, then does the onset, duration,
and magnitude of the leaks affect the exhaled breath sample CFC-113 concentration given that
the overall dose remains the same? If our work shows that the various scenarios of CFC-113
exposure does not influence the exhaled breath concentration of CFC-113, then the differing
onsets and duration of leaks during the 30 minute exercise regiment will not confound the
exhaled breath data for the respirator tests.  In this way, the Coffey studies can be sure that the
end-exhaled breath sample is representative of the dose to which the wearer was exposed and not
a factor of the leak profile.
2In our study, subjects were exposed to different concentrations of CFC-113 for variable
duration while conducting 30-minute exercise regiments. End-exhaled breath samples were
collected 25, 30 and 35 minutes after the exercise regiment and the CFC-113 concentration in the
breath samples was quantified using gas chromatography. Three comparative CFC-113 exposure
scenarios were conducted.
In the first scenario a short duration, high exposure administration of CFC-113 delivered
at the beginning or at the end of the half-hour exercise regiment was compared to a long
duration, low exposure administration delivered at the beginning or at the end of the exercise
regiment. The first scenario questioned whether exhaled breath concentrations from a short
duration exposure to a high concentration (1 min of 500 ppm) was statistically equivalent to
exhaled breath concentration from a long duration exposure to a lower concentration (15.15 min
of 33 ppm and a total dose of 500 ppm-min).
The second study compared breath samples when the 500 ppm of CFC-113 was
administered at the beginning six minutes of the exercise regiment to those when CFC was
administered at the last six minutes of the regiment (total dose 3,000 ppm-min).
The third study compared continuous CFC-113 exposure (30 min of 100 ppm) to
intermittent exposure (three intermittent 2-min exposures of 500 ppm) that results in a total dose
of 3,000 ppm-min.
3Chapter 2
Review of Literature
Properties of CFC-113
CFC-113 serves as an excellent biomarker because of its chemical properties.
Monitoring the exhaled air is best with volatile chemicals such as CFC-113 because they do not
decompose upon contact with tissue, they are insoluble in water and thus in the mucus coating of
the lungs, and their metabolites are not volatile (Fiserova-Bergerova, 1989).  Furthermore,
monitoring the exhaled air is convenient and a simple chemical analysis, although it is
susceptible to intricate changes of concentration during expiration (Fiserova-Bergerova, 1989).
CFC-113 has a molecular weight of 187.38 g/mol and a density of 1.57 g/ml (NIOSH,
1997).  Its solubility into the blood from the lungs is relatively low, and it is only minimally
metabolized, if at all, and is quickly washed out from the tissues in the breath. Since it is quickly
eliminated via the lungs after exposure, CFC-113 acts as a perfect non-toxic challenging agent
for respirator protection.  Exposure can be determined easily by sampling the breath after
exposure.  Post-exposure, the alveolar air is enriched by CFC-113 carried in the blood from the
tissues.  Ideally the concentration of vapor in the end-exhaled air equals the concentration in the
alveolar air (Fiserova-Bergerova, 1989). In this study, I have collected only end-exhaled breath
samples; this reflects the breath at the end of expiration.
 CFC-113 has commercial uses as a degreaser, dry cleaning agent and a refrigerant, thus,
many studies have been conducted in humans and animals to determine its toxicity (Vainio et.
al., 1980; Reinhardt et. al., 1971; Stopps and McLaughlin, 1967).  The studies consider liver
toxicity, psychomotor skills and psychophysiological tests; the tests revealed that CFC-113 has a
4comparatively low degree of toxicity for very elevated concentrations.  The Occupational Safety
and Health Administration (OSHA) Permissible Exposure Limit (PEL), the National Institute of
Occupational Safety and Health (NIOSH) Recommended Exposure Limit (REL) and the
American Conference of Government Industrial Hygienist (ACGIH) Threshold Limit Value
(TLV) for CFC-113 is 1000 ppm as an 8 hour time weighted average (29 CFR 1910.100;
NIOSH, 1997; ACGIH, 1998).  Its principle hazard is narcosis.  This study exposes human
subjects to a variety of CFC-113 concentrations, however, the maximum exposure is 500 ppm of
CFC-113 for 6 minutes, which is well below the PEL.
Pharmacokinetics
The pharmacokinetics of a substance can be loosely defined as the movement that it
undergoes through the body once the body has taken it in via dermal, respiratory, ocular, or
ingestive routes.  The movement entails absorption into the circulatory system, distribution
among the tissues and then elimination from the body through the urine, and as pulmonary wash-
out (Stine and Brown, 1996).
Absorption and elimination are opposite processes and cannot be estimated when both are
in operation.  For some substances the rate of loss from the body is independent of the
concentration in the body and is thus constant over time.  This form of elimination is described
as a zero-order kinetic process.  If however, the elimination of a substance is at first very rapid
and then less rapid with subsequent sampling, it follows a first-order process of elimination.  A
plot of the elimination concentration over time follows a logarithmic decay.  In this case, the rate
of loss is dependent upon the concentration of the substance in the body.  Most substances
5eliminate in a process that resembles first-order pharmacokinetics, however the process is
usually more complicated.
The complication arises because the body does not function as a single compartment.
Substances move between multiple body compartments. How a substance is absorbed and
eliminated from various tissues depends on the lipid content of that tissue, the solubility of the
substance, the location of the tissue and the metabolism of the substance (Fiserova-Bergerova et.
al., 1980, Astrand, 1975).  Therefore there may be 2 or more first-order processes by which the
substance is eliminated.
Although a first-order elimination from a single compartment can be determined from the
log concentration vs. time plot, a multi-compartment model can only determine the final rate
constant from the slowest compartment (Stine and Brown, 1996). Only with more complex
mathematical modeling can the faster processes be estimated.
With lipophilic substances, a simple one-dimensional model is not realistic because there
is poor solubility in the blood plasma and high solubility in the body lipids.  Fatty tissue such as
adipose and liver will dissolve lipophilic substances and only slowly eliminate it over days or
weeks (Stine and Brown, 1996).
Pharmacokinetics of CFC-113
CFC-113 is inhaled into the lungs and penetrates to the alveoli where the force of
diffusion allows it to be exchanged between the air and the blood.  The transfer forms an
equilibrium between the concentrations in the alveolar air and in the arterial blood leaving the
lungs.  The lining of the lungs is only two cells thick and thus transfer occurs very rapidly.  Once
in the blood, CFC-113 is transferred to the tissues of the body depending on the halogenated
6hydrocarbon’s solubility in that tissue compartment.  The body tissues are modeled as a small
number of discrete compartments characterized by specific perfusion rates and partition
coefficients (Auton and Woollen, 1991).
The partition coefficient of a substance describes the solubility of a gas in blood and air
and reflects the quotient between them such that a higher partition coefficient reflects a higher
concentration in the blood as compared to air (Astrand, 1975).  The blood-air partition
coefficients affect the transportation rate of organic solvents from the external environment to
the tissue and visa versa (Fiserova-Bergerova et. al., 1980).   The partition coefficient of CFC-
113 in the blood is quite low at 0.8 (Morgan et. al., 1972).  CFC-113 is absorbed quite slowly
from the alveolar air and washes out rapidly from the tissue through the breath (Morgan et. al.,
1972; Sato and Nakajime, 1979). CFC-113 is good biomarker for challenging respirators because
penetration of the respirator can be associated to CFC-113 in the exhaled breath relatively
quickly after the exposure.
The compartments that are commonly described after absorption into the blood are the
liver, viscera and brain (rapidly perfused tissue), muscle and skin (slowly perfused) and fat
(adipose tissue) (Auton and Woollen, 1991).
Woollen et. al. (1990) described the pharmacokinetics of CFC-113 with a three
compartment model whose average half lives of elimination in breath were 0.22, 2.3 and 29 h.
They exposed 7 volunteers to 1004, 535, and 258 ppm of CFC-113 for 4 hours and analyzed
whole breath samples, end-exhaled breath samples, and blood samples for CFC-113
concentration.  They found that collecting end-exhaled samples produced concentrations that
were consistently higher than whole breath samples (because it is undiluted by dead space in the
7upper respiratory tract).  It is therefore preferable to use this means to collect samples of CFC-
113 from exposed subjects.
In the Woollen et. al. experiment, only 4.3% of the dose was recovered unchanged in the
breath after exposure which they suggested was due to metabolism of CFC-113, but which has
since been shown not to be conclusive (Woollen, 1990; Auton and Woollen, 1991).  They also
found that the low blood:breath ratios where consistent with the low solubility of CFC-113.
In the Woollen et. al. study, the blood concentrations plateaued after approximately 30
minutes of exposure, which suggests that it only takes that long to equilibrate CFC-113 in the
blood.  The breath data showed a consistent downward trend.  The CFC-113 elimination profile
following 4 hour of exposure initially had a very rapid decline (mean t1/2 @ 0.22 h) followed by a
slower decline (mean t1/2 @ 2.3 h). The final phase was a very slow one that could be detected in
the breath 7 days after exposure (mean t1/2 @ 29 h).  Woollen et. al. suggest that the first
compartment corresponds to blood, the second to tissues and the third to fatty tissues.
In a companion study, which used a physiologically based mathematical model to
determine the pharmacokinetics of CFC-113, Auton and Woolen described the absorption,
distribution and elimination of CFC-113 as that of styrene (Auton and Woollen, 1991; Ramsey
and Anderson, 1984).   They measured the breath and blood concentration for volunteers
exposed to 250 ppm CFC-113, and determined that metabolism has only minor influences on the
pharmacokinetics following inhalation exposure.  Furthermore, exhalation remained the major
route of elimination and the rate limiting step for elimination was the perfusion of muscles and
fatty tissue which occurs at a half-life of 1.8 and 41 hours, respectively
Fiserova-Bergerova et. al. (1980) used a  five compartment model to outline the effects of
metabolism and solubility on uptake distribution and exhalation of organic solvents, such as
8CFC-113. They found that rate constants were determined by tissue perfusion, where the five
compartments were the lung tissue, the vessel rich brain, the vapor metabolism tissue (such as
the liver, kidneys, glands, heart, and GI tract), the muscles and skin, and the adipose tissue.  A
significant finding was that the exposure duration has a striking effect on the ratio of the
substance that gets exhaled and metabolized.  More is recovered in the exhaled breath after a
short duration than after a long duration exposure.  Cardiac output also affects pulmonary wash-
out because physical exertion increases solubility (Fiserova-Bergerova et. al., 1984).   These are
relevant findings because my report questions how the exposure duration of CFC-113 affects the
end-exhaled breath concentrations.
Decker and Crutchfield (1993), attempted to define the relationship between measured
respirator fit and actual workplace protection by using CFC-113 as the challenging agent.  They
determined respirator performance through biological monitoring of exhaled air for levels of the
challenging agent, CFC-113.  In order to determine the appropriate sampling times, they describe
an elimination profile for CFC-113 in their subjects. They used the method of residuals or back-
feathering to define CFC-113 elimination curves for their study.  This allowed them to separate a
complex exponential function into its two underlying functions.  In their study each subject was
exposed to 1.25, 6.0 and 12.0 ppm CFC-113 for 30 minutes and breath samples were taken
ranging from 1 minute to 60 minutes post-exposure. They found that their data fit best into a two
compartment pharmacokinetic model, which had the general form:
C = A*exp-ατ  + B*exp-βτ
Where:
C= Concentration in breath
A= Concentration at time 0 for central compartment
9α = first-order elimination rate constant for the central compartment
β = first order elimination rate constant for the peripheral compartment
B= concentration at time 0 for the peripheral compartment
They defined the central compartment as that into which the blood is directly absorbed,
such as the blood and other highly perfused tissues.  The peripheral compartment is that with
which the central compartments interacts. They felt that the since the central and peripheral
compartments had a desaturation half-life of 4.2 and 52 minutes, respectively, that measurement
of the CFC-113 concentration in the breath could begin at 25 minutes.  At 25 minutes post-
exposure the contribution from the central compartment would be minimal.  Their desaturation
curve reaches a plateau at 30 minutes and remains constant for the entire 60 minutes.
The discrepancy between two-compartment model of Decker and Crutchfield and the
three-compartment model of Woollen et. al. lies in the fact that Decker and Crutchfield used
very low concentration of CFC-113 and stopped their analysis at 60 minutes, which is 28h before
the third compartment purge that Woollen et. al. found.
Applying the Pharmacokinetics of CFC-113
The pharmacokinetic findings are relevant to this report because they are the bases of the
decision to use 25, 30 and 35 minutes as the post-exposure breath sampling points. Pilots studies
conducted by Sampas Das agree with the pharmacokinetic studies; the pilot revealed that the
desaturation profile of CFC-113 stabilizes at approximately 30 minutes post exposure (Das,
1995).  This project is a part of the Coffey experiments to relate respirator fit to actual exposure
(Coffey et. al., 1998; Coffey et. al., 1998; Coffey, 1997) and the decision to collect the breath
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samples at 25, 30 and 35 minutes post-exposure is consistent with the experimental design of
those two projects.
Furthermore, the pilot study supports my hypothesis that various 30-minute exposure
scenarios of CFC-113 should not affect the end-exhaled breath concentrations of CFC–113,
because the desaturation profile stays relatively consistent for an hour post exposure.  The
pharmacokinetic studies place the second compartment desaturation half-life at around 1.8 to 2.3
hours post exposure, which implies that if CFC-113 exposure occurs at the very beginning of the
30 minute exercise regiment, the concentration in the breath sample will consist entirely of
peripheral compartment purging.  The maximal duration between exposure and sample collect is
65 minutes and the minimal duration is 25 minutes; the pharmacokinetic models suggest that the
breath sample concentration should be unaffected by the difference in exposure scenarios.
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Chapter 3
Materials and Methods
Subject Selection
A total of 12 subjects were utilized in these series of experiments, four for each phase.
Each of the volunteers for this study participated in the CQAB Human Test Subject Medical
Surveillance Program.  As part of the program, they completed a health questionnaire and
received a medical evaluation when they entered the program and yearly thereafter.  These
evaluations were approved by the NIOSH Human Subjects Review Board. The evaluation also
includes a section on previous exposure to CFC-113. If the subject has a history of exposure to
CFC-113 and resulting symptoms, he/she would not be allowed to participate in the study.
Furthermore, the tests where scheduled so that no subject would be exposed to CFC-113 without
a 72 hour interim between tests.
The type of tests that the subjects performed for this project involved no more than mild
physiologic stress.  The exertion required was no greater than the certification tests for which the
subjects were medically cleared.
Experimental Design
This project was laboratory based. The purpose of this study is to determine if different
CFC-113 exposure scenarios to subjects affect their end-exhaled breath concentrations of CFC-
113.  This study is of interest because CFC-113 has been used a biomarker in numerous
experiments which attempt to correlate respirator fit factors to actual measures of protection
afforded to the respirator wearer (Coffey et.al., 1998; Coffey et. al., 1998; Coffey, 1997; Decker
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and Crutchfield, 1993). The concentration of CFC-113 in the exhaled breath samples, in these
studies, relate to the leaks that occur during the exercise regiment in which the respirator is worn.
The studies attempt to correlate the fit factors of respirators to the simulated workplace exposure;
in these experiments, the exposure is to CFC-113. Within the context of these studies it is
important to determine if the timing and duration of the leaks during the exercise regiment affect
exhaled breath CFC-113 concentrations.  The purpose of this project was to compare various
CFC-113 exposure scenarios of equivalent doses to determine if the timing, duration and peak
amounts affect the amount of Freon-113 that was eliminated in the exhaled breath.
There were three phases to the CFC-113 exposure testing: Phase One, Phase Two, Phase
Three.
Phase One
Phase one compared four separate scenarios: long or short duration exposures
administered at the beginning or end of the exercise regiment.  The issue that this phase of the
study addressed was whether a short duration exposure to a high concentration had the same end-
exhaled breath concentration as a long duration exposure to a lower concentration given that
each total exposure (ppm-minutes) was the same.
The four subjects chosen at random were exposed to three replicates of each of the four
scenarios resulting in a total of 12 tests per subject.  Each subject wore a flexible cup covering
his nose and mouth (nose cup) that was connected to a system that provided either pure
breathing-quality air (grade D) or breathing-quality air containing 15 to 20 mg/m3 corn oil and
one of two concentrations of CFC-113.  The flow rate into the nose cup was 35 LPM.  They
wore the nose cup for 30 minutes and performed the exercise regiment listed below.  During the
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exercise regiment, depending on the test, the subject was administered one of two concentrations
of CFC-113.  After the exercise regiment, subject was taken to a CFC-free waiting room. At 25,
30 and 35 minutes after removing the nose cup, breath samples were collected. The breath
samples were analyzed by a gas chromatograph using both a mass selection detector and an
electron capture device.
For test one (Short, End), the subject breathed breathing-quality air for the first 29
minutes and breathing-quality air containing 15 to 20 mg/m3 of corn oil and 500 ppm of CFC for
the last minute (see Table 3.1- Experiment Design).  In test two (Short, Beginning), the subject
breathed breathing quality air containing 15 to 20 mg/m3 of corn oil and 500 ppm of CFC-113
for the first minute and just breathing quality air for the remaining 29 minutes.  For test three
(Long, Beginning), the subject was placed in a chamber that contained 15-20 mg/m3 of corn oil
and 33 ppm of CFC-113 for the first 14 minutes 51 seconds and was exposed to breathing-
quality air for the remaining 15 minutes and 9 seconds.  While in the chamber, the subjects
donned a Tyvek suit, rubber gloves and goggles to prevent CFC-113 absorption via dermal
routes. In test four (Long, End), the subject breathed air for the first 15 minutes and 9 seconds
and then was put in the chamber to breath air containing 15-20 mg/m3 of corn oil and 33 ppm
CFC-113.  The subjects were exposed to a total of 16.67 ppm (or 500 ppm-min) of CFC-113 in
each tests.
Phase Two.   Beginning vs. End Exposure Scenarios
Phase two consists of only two tests. The four subjects chosen at random were exposed to
three replicates of both scenarios resulting in a total of 6 tests per subject. Phase two compares
the breath sample concentrations when the subject was exposed to CFC-113 at the beginning of
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the exercise regiment to breath sample concentrations when the CFC-113 exposure occurred at
the end of the exercise regiment (see Table 3.1-Experimental Design).  The difference between
this phase and phase one is that the subjects were exposed to a total of 3000 ppm-min of CFC-
113 in this phase (the maximal dose allowable in NIOSH testing).
This testing consisted of four subjects, chosen at random, wearing the nose cup described
above. In test one (Beginning), the subjects were exposed to air containing 15-20 mg/m3 of corn
oil and 500 ppm of CFC-113 for the first 6 minutes of the exercise regiment, and breathing–
quality air for the remaining 24 minutes.  Test two (End) consisted of the subject being exposed
to breathing quality air for the first 24 minutes of the test and to air containing 15-20 mg/m3 of
corn oil and 500 ppm of CFC-113 for the last 6 minutes of testing. The flow rate into the nose
cup was 35 LPM.  They wore the nose cup for 30 minutes and performed the exercise regiment
listed below.   After the exercise regiment, the subject was taken to a CFC-free waiting room. At
25, 30 and 35 minutes after removing the nose cup, breath samples were taken. The breath
samples were analyzed by a gas chromatograph using both a mass selection and an electron
capture detector.
Phase Three.  Continuous vs. Intermittent Exposure Scenarios
Phase three compares a continuous exposure scenario to an intermittent one (see Table
3.1-Experiment Design). The four subjects chosen at random were exposed to three replicates of
both scenarios resulting in a total of 6 tests per subject.   This testing consisted of four subjects,
chosen at random, utilizing the CFC-113 delivery system described above.
In test one (INT), the subjects were intermittently exposed to air containing 15-20 mg/m3
of corn oil and 500 ppm of CFC-113 for the first 2 minutes, the 13th –15th minute and the 28th –
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30th minute of the exercise regiment, and breathing–quality air for the interim 24 minutes.  Each
subject is exposed to a total of 6 minutes of 500 ppm of CFC resulting in 3000 ppm-minutes of
CFC-113 exposure.  Test two (CON) consisted of the subject being exposed air containing 15-20
mg/m3 of corn oil and 100 ppm of CFC-113 for the entire 30 minutes of testing.
The flow rate into the nose cup was 35 LPM.  They wore the nose cup for 30 minutes and
performed the exercise regiment listed below.   After the exercise regiment, the subject was
taken to a CFC-free waiting room. At 25, 30 and 35 minutes post exposure, breath samples were
taken and analyzed by a gas chromatograph.
CFC-113 Delivery System
The CFC delivery system was a modified air brush that aerosolized a source of 1:7 Corn-
oil:CFC-113 solution.  The house air at 35 LPM was used to propel the solution into the
aerosolizer.  Fine tuning of the CFC delivery system allowed for precise adjustments of the CFC-
113 concentration in the nose cup.  A diverting lever was used to divert the CFC-113 to the nose
cup or out the exhaust depending on the experimental design. When the CFC-113 was diverted
out the exhaust, only breathing quality air was directed to the nose cup. The changes in the nose
cup concentration were apparent within seconds.
The concentration of CFC-113 in the nose cup was determined by channeling a small
continuous volume to a Wilks MIRAN-1A infrared analyzer (IR).
For Phase 1, tests 2 and 3, which required very low concentrations of CFC-113 (33ppm),
the CFC delivery system was too imprecise and unstable.  For these tests, the subjects were
placed in a chamber containing 33 ppm CFC-113 and corn oil.  Again the IR was used to
establish and monitor the CFC-113 concentration.  The 4 x 4 x 7 ft chamber was charged by
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injecting 0.510 ml of CFC-113 in the chamber and allowing it to evaporate and equilibrate.
When the test designed called for pure breathing quality air, the subjects would return to the CFC
delivery system and don the nose cup.
Exercise Regiment
In every test of the three phases, the subjects were asked to perform the same exercise
regiment.  This series of movements was the same one used in the Coffey study that compares fit
factors to actual exposure. The exercises are intended to simulate the typical movements made in
the workplace by individuals dealing with TB patients that would stress a respirator seal. The
simulated workplace motions that were used in this study are as follows:
Bending  (2 minutes)
Lifting IV bag onto rack (1 minute)
Injecting syringe into IV bag (1 minute)
Picking up a weight of 25 pounds and carrying it (2 minutes)
Twisting body left to right while turning head side to side (2 minutes)
Opening ambulance doors (1 minute)
Sitting and breathing normally (3 minutes)
Bending at waist and straightening up (3 minutes)
Looking left to right (2 minutes)
Reaching from side to side (2 minutes)
Reaching from waist to overhead (2 minutes)
Sitting and breathing normally (2 minutes)
Nodding and turning head (2 minutes)
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Standing and breathing  normally (2 minutes)
Reaching overhead (1 minute)
Operate control panel (1 minute)
Walking (1 minute)
Breath Sample Collection
When sampling, collecting alveolar air yields the most consistent results (APHA, 1988).
Alveolar breath samples were collected by sampling the expiratory reserve volume. The process
involves a forced expiration that follows a passive exhalation into a plastic sampling tube which
has been fitted with uni-directional diaphragms on both ends.  The proximal end allows air to
enter, while the distal end allows air to exit.  As the subject exhaled the expiratory reserve
volume through the sampler, the distal end of the tube was capped off with a stopcock. Once that
was secure, the proximal end was removed from the mouth and capped off. The samples were
then analyzed with the GC. The sampler was equipped with a clamped plastic tube that
facilitated sample withdrawal.
Breath Sample Analysis
The breath samples were analyzed with a gas chromatograph (GC) equipped with a mass
selector detector (MSD) and an electron capture device (ECD).  ECD gas chromatography
provides excellent analytical sensitivity in this study because CFC-113 has six electronegative
halogens.  The ECD has the added advantage of having low sensitivity to potentially interfering
substances in the breath.  Furthermore, the high boiling point of CFC-113 facilitated separating it
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from the major low boiling point constituents of the breath such as oxygen, nitrogen, carbon
dioxide and water vapor (Decker and Crutchfield, 1993).
The GC/MSD/ECD was calibrated using samples of precisely measured concentrations of
CFC-113 vapor as internal standards. The HP software measured CFC-113 detection as areas
under the CFC-113 peak.  These areas were converted into concentrations (in ppm) using a
calibration ratio generated every two weeks.  The mean of the 25, 30 and 35 minute exhaled
breath time points was used to compare the different tests the subjects underwent.  The means
were analyzed using paired comparison statistics to determine if the different exposure scenarios
were equivalent for each subject.
Exposure Concentration
The nose cup and chamber CFC-113 concentrations were determined prior to each test
and continuously monitored the entire 30 minutes of the exercise regiment with a Wilks
MIRAN-1A IR. The IR was calibrated every two weeks at 33, 100, 500 ppm. At these
concentrations the IR was accurate to 1.0.
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TABLE 3.1-Experimental Design
Phase 1 Long and Short vs. Beginning and End Exposure Scenarios
Test 1
Short, End (SE)
29 min House Air
1 min CFC/ Corn oil (500 PPM)
Test 2
Short, Beginning (SB)
1 min CFC/Corn oil (500 PPM)
29 min House Air
Test 3
Long, Beginning (LB)
15 min 9 sec CFC/Corn oil (33 PPM)
14 min 51 sec House Air
Test 4
Long, End (LE)
14 min 51 sec House Air
15 min 9 sec CFC/Corn oil (33 PPM)
Phase 2  Beginning vs. End Exposure Scenarios
Test 1
Beginning (BEG)
6 min CFC/Corn oil (500 PPM)
24 min House Air
Test 2
End (END)
24 min House Air
6 min CFC/corn oil (500 PPM)
Phase 3 Intermittent vs. Continuous Scenarios
Test 1 
Intermittent (INT)
2 min CFC (500 PPM)
10 min House Air
2 min CFC (500 PPM)
13 min House Air
2 min CFC (500 PPM)
1 min House Air
Test 2
Continuous (CON)
30 min CFC (100 PPM)
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Chapter 4
Results
The exhaled breath samples were analyzed at 25, 30 and 35 minutes post exposure and
quantitated as area under the CFC-113 peaks.  The ECD data for all phases is presented in
Appendix A.  The table lists subject number, test conducted, date the test was conducted, and
each of the three post exposure breath samples (recorded as area under the CFC-113 peak).  Only
the data collected with the ECD was used in the analysis.  Approximately every 2 weeks the GC
was calibrated using given concentrations of CFC-113 (see Chapter 4 Materials and Methods--
Breath Sample Analysis) and a linear regression line was constructed from the graph of CFC-113
concentration verses area under the CFC-113 peak. The line took the form y=ax, where "a"
represents the conversion coefficient, "y" represents the area values, and "x" represents the CFC-
113 concentration in ppm (See Appendix C for Calibration Graphs).  Table 4.1 lists the
conversion coefficients and the calibration dates that were used to convert exhaled breath
sampling areas to concentration in ppm.  Each ECD area value was divided by the appropriate
conversion coefficient to yield the CFC-113 concentration in ppm.  The coefficient calculated on
3/25/98 is several fold larger than the previous ones because a filament was changed in the GC
and the autotune setting was changed from standard to maximum.
Phase One Results
Phase 1 compares the short duration, high exposure administration of CFC-113 delivered
at the beginning (Short, Beginning or SB) or at the end (Short, End or SE) to a long duration, low
exposure administration delivered at the beginning (Long, Beginning or LB) or at the end (Long,
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End or LE) of the exercise regiment.  The SB and SE scenarios expose the subjects to 500 ppm
of CFC-113 for 1 minute whereas the LB and LE scenarios expose the subjects to 33 ppm CFC-
113 for 15.15 minutes.  There were four subjects in this phase, Subject 1, 45, 5 and 8.  The
different scenarios were compared only within subjects and inter-subject variability was not
considered.
Tables 4.2a, 4.3a, 4.4a, 4.5a list the date each test was conducted, the converted CFC-113
exhaled breath concentrations for the 25, 30 and 35-minute post-exposure samples for each test,
and the mean and standard deviation values for the three time points for Subjects 1., 45, 5 and 8,
respectively.  Figures 4.1, 4.2, 4.3, and 4.4 graphically depict the mean exhaled breath
concentrations for each repetition of each test for the subjects of phase one. Tables 4.2b, 4.3b,
4.4b, and 4.5b list the mean and standard deviation (SD) for each scenario type for each subject
respectively.  The statistical analysis of these data is presented in Chapter 5.
Subject 1
 The SE had an average breath concentration of 0.63 ± 0.03 ppm with a CV of 6%
(Tables 4.2a and 4.2b). The SB test had an average breath concentration of 0.57 ± 0.06 ppm with
a CV of 11%.  LE had the highest average breath concentration of 0.67 ± 0.25 ppm and the
highest CV of 37%.  The LB scenario had an average exhaled breath concentration of 0.56 ±
0.14 ppm with a CV of 25%.  Although the mean values of each scenario are very similar,
standard deviation of the LE test shows a large distribution.  It is clear even without conducting
any statistical analysis that for Subject 1 the four different scenarios produced equivalent exhaled
breath concentrations. Therefore for this subject variable onsets, duration, and magnitude of
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CFC-113 exposure does not alter the exhaled breath concentrations at the 25, 30 and 35 minute
post-exposure points so long as the overall dose is equivalent.
Subject 45
The results for Subject 45 show more variability than Subject 1 both in the means
between each scenario and within the means of each scenario. The SE scenarios had an average
breath concentration of 0.92 ± 0.12 ppm with a CV of 13%.  The SB tests had an average breath
concentration of 0.69 ± 0.02 ppm with a CV of 3%.  LE had an average concentration of 0.51±
0.14 ppm and a CV of 27%.  The LB tests had an average exhaled breath concentration of 0.89 ±
0.35 ppm with a CV of 40%.
Subject 5
The results for Subject 5 also show considerable variability between the means of each
scenario. The SE scenarios had an average breath concentration of 0.78 ± 0.10 ppm with a CV of
13%. The SB tests had an average breath concentration of 0.74 ± 0.14 ppm with a CV of 19%.
The LE tests had an average concentration of 0.42 ± 0.10 ppm and a CV of 23%.  The LB
scenario had an average exhaled breath concentration of 0.57 ± 0.27 ppm with a CV of 48%.
Although the mean values of each scenario are dissimilar, all but the LB scenario have small
CVs.  With this subject, the SE scenario has the highest average exhaled breath concentration
and LE has the lowest.  The mean values of the SE and the SB tests are similar, while the LE and
LB mean values are similar.
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Subject 8
The results for Subject 8 are depicted in Table 4.5b.  There is very little variability within
scenarios (Figure 4.4 and Table 4.5b) and all but LB show very similar mean exhaled breath
concentrations.  The SE scenario had an average breath concentration of 0.69 ± 0.03 ppm with a
CV of 4%.  The SB test had an average breath concentration of 0.70 ± 0.11 ppm with a CV of
16%.  LE had an average concentration of 0.76 ± 0.19 ppm and the highest CV of 26%.  The LB
scenario had an average exhaled breath concentration of 0.54 ± 0.11 ppm with a CV of 21%. The
CVs ranged from 4% to 24%, which suggests that the precision falls within reasonable
parameters.
Phase Two Results
Phase 2 compares breath samples when 500 ppm of CFC-113 was administered at the
beginning six minutes (BEG) of the exercise regiment to those when CFC was administered at
the last six minutes of the regiment (END).  Four subjects were used for this phase, Subjects 3,
16, 22 and 26.  The different scenarios were compared only within subjects since inter-subject
variability could not be eliminated.  
Tables 4.6a, 4.7a, 4.8a and 4.9a show the date each test was conducted, the converted
CFC-113 exhaled breath concentrations for the 25, 30 and 35-minute post-exposure samples,  the
average concentration and standard deviation for each test for Subjects 3, 16, 22 and 26,
respectively. Tables 4.6b, 4.7b, 4.8b, and 4.9b summarize the mean, standard deviation and CV
of both the BEG and END scenarios for each subject. Figures 4.5, 4.6, 4.7, and 4.8 graphically
depict the mean exhaled breath concentrations for each repetition of each test.
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Subject 3
The BEG scenario had an average exhaled breath concentration of 1.34 ± 0.58 ppm with
a CV of 43%. The END test had an average concentration of 1.51 ± 0.68 ppm with a CV of 45%.
Although the mean breath concentrations for both tests are quite similar, the individual breath
samples show a wide distribution in both scenarios, thus there is very little precision between
repetitions of the same test (Figure 4.5, Table 4.6b).
Subject 16
The results for Subject 16 show more variability than the results for Subject 3. The BEG
scenario yielded an average exhaled breath concentration of 1.37 ± 0.56 ppm with a CV of 41%.
The END tests showed an average concentration of 1.94 ± 0.70 ppm with a CV of 36%.
Although the mean breath concentrations for both tests show some difference, the individual
breath samples show a large distribution in both scenarios, thus there is questionable precision
between repetitions of the same test (Figure 4.6 and Tables 4.7a and 4.7b).
Subject 22
Subject 22 tests revealed considerably less variability than Subject 16.  The BEG
scenarios yielded an average exhaled breath concentration of 1.57 ± 0.25 ppm with a CV of 16%
(Table 4.8b).  The END tests showed an average concentration of 1.57 ± 0.43 ppm with a CV of
27% (Table 4.8b).  The mean breath concentrations for both tests are exactly the same. The mean
breath samples for both BEG and END tests show good precision (Figure 4.7 and Table 4.8a).
For Subject 22 it is clear that CFC-113 exposure at the beginning of the exercise regiment does
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not influence the exhaled breath concentrations any more than exposure at the end of the
regiment so long as the overall dose is equivalent.
Subject 26
The results for Subject 26 yielded the most variation. The BEG scenarios yielded an
average exhaled breath concentration of 1.04 ± 0.25 ppm with a CV of 24%. (Table 4.9b). The
END tests showed an average concentration of 1.83 ± 0.35 ppm with a CV of 19% (Table 4.9b).
Although the mean breath concentrations for both tests are not similar, the mean breath samples
in the BEG tests show a smaller distribution than the END tests, thus there is more precision
between repetitions of the BEG tests (Figure 4.8 and Table 4.9a).  However, the precision varied
from 19% to 24%, which is within acceptable limits.
Phase Three Results
Phase 3 compares continuous CFC-113 exposures (CON), 30 minutes of 100 ppm, to
intermittent exposures, three intermittent 2-minute exposures of 500 ppm (INT).  Four subjects
were used for this phase, Subjects 4, 10, 19 and 29.  The different scenarios were compared
within subjects.
Tables 4.10a, 4.11a, 4.12a and 4.13a show the date that the test were conducted, the
converted CFC-113 exhaled breath concentrations for the 25, 30 and 35-minute post-exposure
samples, and the mean and standard deviation of the three time points for each test for Subjects
4, 10, 19, and 29, respectively. Figures 4.9, 4.10, 4.11 and 4.12 graphically depict the mean
exhaled breath concentrations for each repetition of each test of each of the four subjects. Tables
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4.10b, 4.11b, 4.12b, and 4.13b list the mean, SD and CV for each scenario type for Subjects 4,
10, 19, and 29, respectively.
Subject 4
The CON scenarios yielded an average exhaled breath concentration of 1.44 ± 0.27 ppm
with a CV of 19% (Table 4.10b). The INT tests showed an average concentration of 1.23 ± 0.33
ppm with a CV of 27% (Table 4.10b).  The mean breath concentrations for both tests are quite
similar, and the mean breath samples in both the CON and INT tests show fairly good precision
between repetitions of the tests (Figure 4.9 and Table 4.10a).
Subject 10
The INT scenarios yielded an average exhaled breath concentration of 1.15 ± 0.32 ppm
with a CV of 28% (Table 4.11b). The CON tests showed an average concentration of 1.15 ± 0.34
ppm with a CV of 30% (Table 4.11b).  Although the mean breath concentrations for both tests
are the same, the mean breath samples for both scenarios show a good deal of variability (Figure
4.10 and Table 4.11a).  For this subject, a comparison of the mean exhaled breath samples were
the same for both a continuous and an intermittent exposure, thus the nature of CFC-113
exposure does not bias the exhaled breath sample concentration.
Subject 19
The results for Subject 19 are not as definite as those for Subject 10. The INT scenarios
yielded an average exhaled breath concentration of 0.93 ± 0.21 ppm with a CV of 23% (Table
4.12b).  The CON tests showed an average concentration of 1.24 ± 0.41 ppm with a CV of 33%
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(Table 4.12b).  Although the mean breath concentrations for both tests are similar, the mean
breath samples in the CON scenario show slightly less precision than the INT test (Figure 4.11
and Table 4.12a).
Subject 29
The results for Subject 29 yielded more variation than those of Subject 19 with CV
ranging from 36% to 43%.  The INT scenarios yielded an average exhaled breath concentration
of 2.01 ± 0.86 ppm with a CV of 43% (Table 4.13b).  The CON tests showed an average
concentration of 1.63 ± 0.60 ppm with a CV of 36% (Table 4.13b).  Although the mean breath
concentrations for both tests are similar, the variability is rather high in both (Figure 4.12 and
Table 4.13a).
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TABLE 4.1
Area to Concentration Conversion Coefficients for the ECD-GC
Calibration Date Coefficent
1/9/98 97802
2/23/98 99910
3/9/98 80211
3/23/98 77279
3/25/98 186508
Note: The line took the form y=ax, where "a" represents the conversion coefficient,
"y" represents the area values, and "x" represents the CFC-113 concentration in ppm.
 See Appendix C for Calibration Graphs.
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TABLE 4.2a
Phase 1 Results for Subject 1
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
1 3/5/98 SE 0.70 0.58 0.71 0.66 0.07
1 3/27/98 SE 0.67 0.57 0.51 0.58 0.08
1 3/31/98 SE 0.65 0.64 0.62 0.64 0.01
1 2/20/98 SB 0.67 0.52 0.74 0.64 0.11
1 2/24/98 SB 0.60 0.56 0.50 0.55 0.05
1 3/19/98 SB 0.56 0.51 0.48 0.52 0.04
1 2/2/98 LE 0.97 0.87 0.89 0.91 0.05
1 2/6/98 LE 0.71 0.62 0.74 0.69 0.06
1 2/27/98 LE 0.46 0.40 0.38 0.41 0.04
1 2/13/98 LB 0.69 0.67 0.64 0.67 0.03
1 4/9/98 LB 0.57 0.62 0.63 0.61 0.03
1 3/26/98 LB 0.34 0.38 0.48 0.40 0.07
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
Note: SE= Short, End; SB= Short, Beginning; LE= Long, End; LB= Long, Beginning
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TABLE 4.2b
Summary of Results for Subject 1
Test Mean +/- SD CV (%)
SE 0.63 0.04 6
SB 0.57 0.06 11
LE 0.67 0.25 37
LB 0.56 0.14 25
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Figure 4.1 Comparison of Phase 1 Scenarios for Subject 1
Trial 1
Trial 2
Trail 3
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TABLE 4.3a
Phase 1 Results for Subject 45
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
45 2/5/98 SE 1.29 1.07 0.83 1.06 0.23
45 4/15/98 SE 0.88 0.72 0.91 0.83 0.10
45 4/17/98 SE 0.88 0.83 0.89 0.87 0.04
45 2/12/98 SB 0.70 0.67 0.72 0.69 0.02
45 3/31/98 SB 0.67 0.74 0.71 0.71 0.03
45 4/14/98 SB 0.67 0.67 0.66 0.67 0.00
45 3/26/98 LE 0.38 0.33 0.37 0.36 0.03
45 4/10/98 LE 0.54 0.51 0.51 0.52 0.02
45 4/16/98 LE 0.65 0.60 0.66 0.64 0.03
45 2/19/98 LB 0.75 0.71 0.74 0.73 0.02
45 3/20/98 LB 1.23 1.09 1.55 1.29 0.23
45 3/27/98 LB 0.60 0.64 0.68 0.64 0.04
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
Note: SE= Short, End; SB= Short, Beginning; LE= Long, End; LB= Long, Beginning
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TABLE 4.3b
Summary of Results for Subject 45
Test Mean +/-SD CV (%)
SE 0.92 0.12 13
SB 0.69 0.02 3
LE 0.51 0.14 27
LB 0.89 0.35 40
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Figure 4.2 Comparison of Phase 1 Scenarios for Subject 45
Trial 1
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Trail 3
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TABLE 4.4a
Phase 1 Results for Subject 5
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
5 2/3/98 SE 0.82 0.75 0.75 0.77 0.04
5 2/24/98 SE 0.79 0.64 0.64 0.69 0.09
5 3/17/98 SE 0.95 0.87 0.85 0.89 0.05
5 2/6/98 SB 0.81 0.68 0.66 0.72 0.08
5 2/17/98 SB 0.92 0.97 0.75 0.88 0.12
5 3/3/98 SB 0.66 0.63 0.54 0.61 0.06
5 1/23/98 LE 0.36 0.38 0.30 0.35 0.04
5 1/30/98 LE 0.41 0.39 0.38 0.40 0.02
5 2/13/98 LE 0.52 0.53 0.55 0.53 0.01
5 1/28/98 LB 0.39 0.40 0.45 0.41 0.03
5 2/10/98 LB 0.74 1.01 0.90 0.88 0.13
5 2/27/98 LB 0.44 0.39 0.40 0.41 0.03
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
Note: SE= Short, End; SB= Short, Beginning; LE= Long, End; LB= Long, Beginning
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TABLE 4.4b
Summary of Results for Subject 5
Test Mean -/+ SD CV (%)
SE 0.78 0.10 13
SB 0.74 0.14 19
LE 0.42 0.10 23
LB 0.57 0.27 48
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Figure 4.3 Comparison of Phase 1 Scenarios for Subject 5
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TABLE 4.5a
Phase 1 Results for Subject 8
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
8 2/10/98 SE 0.70 0.68 0.61 0.66 0.05
8 3/3/98 SE 0.76 0.60 0.79 0.72 0.10
8 3/26/98 SE 0.70 0.77 0.63 0.70 0.07
8 2/5/98 SB 0.84 0.85 0.79 0.83 0.03
8 2/24/98 SB 0.63 0.64 0.69 0.65 0.03
8 4/1/98 SB 0.64 0.56 0.64 0.62 0.05
8 2/12/98 LE 0.64 0.63 0.69 0.65 0.03
8 2/26/98 LE 0.78 0.57 0.57 0.64 0.12
8 3/19/98 LE 0.97 0.94 1.04 0.98 0.05
8 1/30/98 LB 0.43 0.42 PROB 0.42 0.01
8 2/17/98 LB 0.58 0.63 0.70 0.64 0.06
8 2/19/98 LB 0.47 0.57 0.66 0.57 0.09
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
Note: SE= Short, End; SB= Short, Beginning; LE= Long, End; LB= Long, Beginning
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TABLE 4.5b
Summary of Results for Subject 8
Test Mean +/- SD CV (%)
SE 0.69 0.03 4
SB 0.70 0.11 16
LE 0.76 0.19 26
LB 0.54 0.11 21
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Figure 4.4 Comparison of Phase 1 Scenarios for Subject 8
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 TABLE 4.6a
Results for Subject 3 Comparison of Beginning vs. End Scenarios
TABLE 4.6b
Summary of Results for Subject 3
Test Mean +/- SD CV (%)
BEG 1.34 0.58 43
END 1.51 0.68 45
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
3 2/6/98 BEG 1.91 1.85 1.71 1.82 0.10
3 2/20/98 BEG 1.40 1.55 1.53 1.50 0.08
3 3/27/98 BEG 0.67 0.64 0.80 0.70 0.09
3 2/13/98 END 0.85 0.74 0.87 0.82 0.07
3 2/27/98 END 1.53 1.53 1.52 1.53 0.01
3 3/20/98 END 2.61 2.11 1.80 2.17 0.41
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
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Figure 4.5 Comparison of Beginning vs. End Scenarios for Subject  3
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TABLE 4.7a
Results for Subject 16 Comparison of Beginning vs. End Scenarios
TABLE 4.7b
Summary of Results for Subject 16
Test Mean +/- SD CV (%)
BEG 1.37 0.56 41
END 1.94 0.70 36
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
16 2/2/98 BEG 2.40 1.99 1.61 2.00 0.40
16 2/23/98 BEG 0.90 1.03 0.92 0.95 0.07
16 3/3/98 BEG 1.22 1.21 1.02 1.15 0.11
16 3/17/98 END 2.17 1.98 1.71 1.95 0.23
16 3/20/98 END 3.10 2.50 2.29 2.63 0.42
16 3/31/98 END 1.42 1.17 1.14 1.24 0.15
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
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TABLE 4.8a
Results for Subject 22 Comparison of Beginning vs. End Scenarios
TABLE 4.8b
Summary of Results for Subject 22
Test Mean +/- SD CV (%)
BEG 1.57 0.25 16
END 1.57 0.43 27
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
22 2/5/98 BEG 1.56 1.14 1.26 1.32 0.22
22 2/26/98 BEG 1.68 1.69 1.34 1.57 0.20
22 3/5/98 BEG 2.19 1.76 1.48 1.81 0.36
22 1/29/98 END 2.36 2.08 1.75 2.06 0.30
22 2/12/98 END 1.59 1.36 1.13 1.36 0.23
22 2/19/98 END 1.71 1.24 0.89 1.28 0.41
CFC-113 EXHALED BREATH CONCENTRATION 
(PPM)
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TABLE 4.9a
Results for Subject 26 Comparison of Beginning vs. End Scenarios
TABLE 4.9b
Summary of Results for Subject 26
Test Mean +/-SD CV (%)
BEG 1.04 0.25 24
END 1.83 0.35 19
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
26 1/23/98 BEG 0.98 1.04 0.72 0.91 0.17
26 2/13/98 BEG 0.94 0.87 0.82 0.88 0.06
26 2/26/98 BEG 1.41 1.34 1.22 1.32 0.10
26 1/29/98 END 1.40 1.46 PROB 1.43 0.04
26 2/3/98 END 2.71 1.84 1.41 1.99 0.66
26 3/19/98 END 2.21 1.96 2.07 2.08 0.13
CFC-113 EXHALED BREATH CONCENTRATION 
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Figure 4.8 Comparison of Beginning vs. End Scenarios for Subject  26
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TABLE 4.10a
Results for Subject 4 Comparison of Continuos vs. Intermittent Scenarios
TABLE 4.10b
Summary of Results for Subject 4
Test Mean +/- SD CV (%)
INT 1.23 0.33 27
CON 1.44 0.27 19
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
4 1/23/98 INT 0.91 1.08 1.18 1.05 0.14
4 2/13/98 INT 1.40 0.81 0.90 1.03 0.32
4 2/20/98 INT 1.86 1.49 1.48 1.61 0.22
4 1/30/98 CON 1.54 1.44 1.03 1.34 0.27
4 2/6/98 CON 1.97 1.68 1.60 1.75 0.19
4 2/27/98 CON 1.34 1.50 0.90 1.25 0.31
CFC-113 EXHALED BREATH CONCENTRATION 
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Figure 4.9 Comparison of Intermittent vs. Continuous Scenarios for Subject 4
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TABLE 4.11a
Results for Subject 10 Comparison of Intermittent vs. Continuous Scenarios
CFC-113 EXHALED BREATH
CONCENTRATION (PPM)
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
10 2/3/98 INT 1.50 1.66 1.39 1.52 0.13
10 3/17/98 INT 0.92 1.04 0.82 0.93 0.11
10 3/24/98 INT 1.41 0.67 0.90 0.99 0.38
10 1/28/98 CON 1.20 1.16 0.79 1.05 0.23
10 2/10/98 CON 1.57 1.36 1.65 1.53 0.15
10 2/24/98 CON 1.00 0.83 0.79 0.87 0.11
TABLE 4.11b
Summary of Results for Subject 10
Test Mean +/-SD CV (%)
INT 1.15 0.32 28
CON 1.15 0.34 30
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Figure 4.10 Comparison of Intermittent vs. Continuous Scenarios for Subject 10
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TABLE 4.12a
Results for Subject 19 Comparison of Intermittent vs. Continuous Scenarios
CFC-113 EXHALED BREATH
CONCENTRATION (PPM)
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
19 2/19/98 INT 0.79 0.70 0.59 0.69 0.10
19 2/26/98 INT 1.36 0.98 0.96 1.10 0.23
19 3/5/98 INT 1.17 1.01 0.83 1.00 0.17
19 2/5/98 CON 2.04 1.67 1.35 1.69 0.34
19 2/12/98 CON 1.27 1.20 0.98 1.15 0.15
19 4/2/98 CON 0.88 0.83 0.98 0.89 0.08
TABLE 4.12b
Summary of Results for Subject 19
Test Mean +/-SD CV (%)
INT 0.93 0.21 23
CON 1.24 0.41 33
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TABLE 4.13a
Results for Subject 29 Comparison of Intermittent vs. Continuous Scenarios
CFC-113 EXHALED BREATH
CONCENTRATION (PPM)
Subject Date Test 25 min. 30 min. 35 min. Mean +/- SD
29 2/20/98 INT 1.64 1.65 1.31 1.53 0.20
29 2/27/98 INT 1.70 1.37 1.38 1.49 0.19
29 3/20/98 INT 3.21 2.80 2.98 3.00 0.21
29 1/30/98 CON 1.72 1.66 1.56 1.65 0.08
29 2/6/98 CON 2.32 2.29 2.06 2.22 0.14
29 2/13/98 CON 0.99 1.17 0.94 1.03 0.12
TABLE 4.13b
Summary of Results for Subject 29
Test Mean +/- SD CV (%)
INT 2.01 0.86 43
CON 1.63 0.60 36
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Chapter 5
Statistical Analysis
Statistical analysis was performed by using the Statistical Analysis System (SAS)
software (SAS Institute, Research Triangle, NC).  A general linear models procedure was
performed on each subject's data and Duncan's Multiple Range Test for variance was performed
to compare the means of each scenario for each subject.  These results are presented in Appendix
D--SAS Results. A significance level of 5% was used in all cases (α = 0.05).
For Phase 1, which compares the means of LB to LE to SB to SE, the Duncan's Test
found no significant difference between the means of each of these scenarios for Subjects 1 and
8.  However, the Duncan's Test showed the following grouping for Subjects 5 and 45:
Subject 5
Duncan Grouping Mean N Test
A 0.7833 3 SE
B A 0.7367 3 SB
B A 0.5667 3 LB
B 0.4267 3 LE
Subject 45
Duncan Grouping Mean N Test
A 0.9200 3 SE
B A 0.8867 3 LB
B A 0.6900 3 SB
B 0.5067 3 LE
Means with the same letter are not significantly different. Note that with both subjects SE, SB
and LB make up one Duncan group, while LB, SB and LE make up another.  For both these
subjects the SE tests are significantly different from the LE tests.  By the General Linear Models
Procedure the P value for subject 45 is 0.1106 and the P value for Subject 5 is 0.1019.  Thus for
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Subjects 1 and 8, the concentration of end-exhaled breath samples were independent of both the
amount and timing of the CFC-113 exposure so long as the dose remained equivalent.  For
Subjects 5 and 45, all the scenarios are equivalent, except that the SE test tends to yield the
highest concentrations which are significantly different from the means of the LE tests. For
Subjects 45 and 5, and not for Subjects 1 and 8, the SE and the LE scenarios distinguish from
each other.
The General Linear Models Procedure and the Duncan test performed on the means of
the Phase 2 scenarios (CFC administered at the end or beginning of the exercise regiment)
determined that there was no significant differences in the mean values of the end-exhaled breath
samples collected. This was the case for all four subjects tested in Phase 2.  Therefore the
concentration of the end-exhaled breath samples were not significantly dependent upon timing of
the CFC exposure.
The General Linear Models Procedure and the Duncan test performed on the means of
the Phase 3 scenarios (CFC administered either continuously or intermittently during the exercise
regiment) determined that there was no significant difference in the mean values of the end-
exhaled breath samples collected. This was the case for all four subjects tested in Phase 3.
Therefore the concentration of the end-exhaled breath samples were not significantly dependent
upon the nature of the CFC exposure given that the overall dose remained equivalent.
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Chapter 6
Discussion and Conclusion
Scenario Equivalence
Whether the comparison is between high concentration at the beginning or end of the
exercise regiment or low doses at the beginning or end of the regiment, the statistical analysis of
phase one reveals that there is no significant differences between the mean concentrations of
each scenario, except between the SE and LE scenarios in two cases.  These scenarios ranged
from a one-minute exposure of 500 ppm CFC to 15.15 minutes of 33 ppm of CFC; the overall
dose in any case was 500 ppm-min.  Furthermore the Phase 2 study revealed that the end-exhaled
breath sample concentrations are independent of the timing of the exposure, whether it occur at
the beginning or the end of the exercise regiment. The statistical analysis revealed that the means
were not significantly different. In each case the exposure was a 6 minute administration of 500
ppm, which was an overall dose of 3,000 ppm-min.  The nature of the administration, whether
intermittent or continuous, did not affect the exhaled breath concentration either.
It is not surprising that the timing, duration, or nature of the CFC administration does not
confound the breath concentration data because the previous studies on this topic suggest as
much.   The pharmacokinetics of CFC-113 reveals that CFC-113 has an average half-life of
elimination in breath at 0.22 hr in some cases and 4.2 and 52 minutes in other cases; the
desaturation curve reaches a plateau at 30 minutes post-exposure and remains constant for the
entire 60 minutes (Woolen et. al., 1990; Auton and Woolen, 1991; Decker and Crutchfield, 1993;
Das, 1996).  These studies also suggest that it takes CFC-113 25 minutes to equilibrate in the
blood.  The desaturation profile for the first 20 minutes represents first compartment purging (i.e.
CFC-113 transferring from the blood to the lungs), while the 2nd compartment purges at a
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constant rate during 30 to 60 minutes post-exposure. Since our experiments consisted of a CFC
exposure during a 30 minute exercise regiment followed by at least 25 minutes of no exposure
before the first breath sample, the longest time between exposure and sample collection would be
54 minutes (SB scenario) whereas the shortest time would be 25 minutes (as with the SE
scenario).  Both the longest duration and the shortest duration between exposure and sample
collection fall within the time period where the CFC has equilibrated in the blood and
elimination has stabilized. During this time the elimination represents second compartment
purging. Indeed the statistical analysis of all four subjects tested in Phase 1 reveal that the SB
and SE scenarios are not significantly different.
One counterintuitive finding was that for two subjects, the mean exhaled breath samples
of the SE tests were significantly different from those from the LB scenarios.  It is difficult to
speculate why an high concentration exposure administered at the very last minute of the
exercise regiment would result in very different exhaled breath samples than a low concentration
exposure administered during the first 15 minutes of the regiment. Perhaps this difference
reflects the variable time needed to equilibrate a CFC-113 exposure in the residual lung volume
when the CFC is present as a large concentration short pulse rather than a low concentration long
pulse.   It is reasonable to assume that with the long pulse of 15 minutes, the CFC in residual
lung volume would have equilibrated and diffused into the blood.  Perhaps with a short pulse of a
large concentration, the residual lung volume takes longer to equilibrate. This, in turn, may
delay the transfer of CFC from the lungs to the blood and thus delay the desaturation profile,
thereby extending the first compartment purging passed the 25 minute sample collection time
point.  Since greater concentrations of CFC-113 are eliminated during the first compartment
purging, if such a shift occurred in the desaturation profile, then the SE test would yield higher
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mean concentrations than the other scenarios (as with the cases of Subject 5 and 45).  Because
the sample collect occurs right at the cusp of the secondary compartment purging, an
equilibration delay of a few minutes may dramatically affect the exhaled breath concentrations.
The exhaled breath samples may have yielded more consistent results if the collection time were
delayed by 10 minutes. There is precedence for this line of reasoning, Fiserova-Bergerova et. al.
(1984) noted that the equilibration rate depends the rate at which the chemical is transferred from
the environment and that the rate limiting factors are pulmonary ventilation, cardiac output,
tissue perfusion, tissue volume and biosolubility.  Furthermore, studies have shown that with low
solubility gases, such as CFC-113, more of the uptake is recovered in the exhaled air after a
shorter exposure than after a longer one (Fiserova-Bergerova et. al., 1980).
Variance
It is noteworthy that the breath samples for some scenarios had such a high coefficient of
variation. This suggests that the method for measuring exposure is imprecise.  Although great
care was taken to collect end-exhaled breath samples from the subjects, the imprecision may be
attributed to the variability with which a subject exhaled into the breath sampler. If the samples
do not represent the end-exhaled breath then there is a risk that the CFC would be diluted with
the air from the upper lungs.  Furthermore, since cardiac output affects CFC-113 absorption into
the lungs and consequently into the blood stream, if there is inconsistency in how vigorously the
subject engages in the exercises from test to test, this would also influence the amount of CFC-
113 that would be absorbed and then eliminated from the body.  His emotional state, his health
or even his body temperature would also affect a subject's heart rate.
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A great deal of variability is introduced into any test that uses human subjects. Many
unconsidered physiological factors can alter the desaturation profile of CFC-113 in the body. For
instance, subjects who are susceptible to asthma or allergies, may experience an increase in
mucus build up in the lungs sporadically that would diminish CFC-113 absorption.  Smoking and
its long-term damage may delay absorption and elimination.  Something as simple as a common
cold may add variation to the replicates.
The variation may also be a factor of the devices used in this study. Some variability can
be attributed to the variation within the breath samplers themselves. It is not that the variation
was due to how the CFC was administered because even when the CFC was administered
continuously throughout the 30-minute regiment, the CVs ranged from 19% to 43%.  Therefore
an argument can not be made that perhaps the functional limitations of starting and stopping the
CFC delivery system, or of reaching the target concentration during the exposure period
contributed to the variability.  Likewise, the CVs were just as high, if not higher, when the CFC
was administered via a charged chamber rather than by the CFC-delivery system.  The
concentration within a charged chamber could be stably and consistently maintained for hours at
a time, yet exhaled breath samples collected after this type of exposure had CVs as high as 37%
and 25% for Subject 1 (Chapter 4, Table 4.2b), 40% and 27% for Subject 45  (Chapter 4, Table
4.3b), 26% and 21 % for Subject 8 (Chapter 4, Table 4.5b) and then as high as 23% and 48% for
Subject 5 (Chapter 4, Table 4.4b).
A great deal of variability can be attributed to the GC conversion coefficients.  The data
gets converted from area to concentration by using the conversion coefficients calculated when
the GC is calibrated.  Any errors incurred during calibration or due to GC fluctuation may
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greatly influence the concentration values.  Likewise, errors incurred during calibration of the IR
may have cause variation from test to test.
Regardless of the cause of the variation, the high degree of variability among the breath
samples of the same test no doubt contributed to a high least significant studentized range in the
Duncan procedure.  The range of any subset of p sample means must exceed the least significant
range before any of the p means are found to be different (Walpole and Myers, 1985).  The
sample variance influences the least significant studentized range.  Therefore a high degree of
variance in the breath samples makes it very difficult for the compared scenario means to be
significantly different.
The Duncan's Multiple Range Test for variance was used because it is considered one of
the most powerful test, however conducting a Tukey's Test or a Least Significant Difference
(LSD) Method on the data would have further validated the findings.  The number of replicates
was limited to 3 per test for economic and logistics reasons. However, increasing the replicates
would increase the power of the Duncan test because this test requires a greater observed
difference to detect significantly different pairs of means as the number of means included in the
group increases (Walpole et. al., 1998).
Trends
Although the statistical analysis shows that there are no significant differences between
the mean values of the compared scenarios, there do appear to be trends in the data that suggest
more intuitive pharmacokinetic mechanisms. With continuous verses intermittent exposures it is
difficult to predict which scenario would yield the highest breath concentrations. A continuous
exposure might yield a higher breath concentration because the body is exposed to a continuous
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amount over the 30-minute exercise regiment, and one may predict that the CFC has equilibrated
in the blood and is continuously being purged during the following 30 minutes. On the other
hand, an intermittent exposure exposes the subject to higher concentrations of CFC for shorter
periods of time, the last of which is 1 minute before the exercise regiment ends. This may lead to
a larger amount of CFC being purged during the collection period roughly 30 minutes post-
exposure.  With Subjects 19 and 4, it appears that the breath concentrations after the CON
exposure were greater than after the INT exposures.  However, for Subject 10 the mean breath
concentrations for each trial of both the CON and the INT scenarios are the same. The general
trend in these tests suggests that there was no significant difference between continuous or
intermittent exposures, however the CON breath samples tend to contain higher concentrations
of CFC-113.  This implies that in respirator test leaks that occur continuously over the entire
exercise period may not result in significantly different breath concentrations than leaks that
occur intermittently throughout the exercise regiment; they may, however, tend to yield slightly
higher concentrations.
The BEG vs. END scenarios in phase two tend to yield higher concentrations in the END
tests than the BEG tests.  In general the statistical analysis and the general trends agree that
exposures administered at the beginning of the regiment do not result in different breath
concentration than exposure administered at the end of the regiment. This implies that the onset
of the leaks either at the beginning or the end of the exercise regiment should not bias the breath
sample data, however leaks occurring at the end of the 30 minute exercise might yield slightly
higher concentrations than those occurring at the beginning..
The phase one scenario results are a little more difficult to predict. One would expect that
regardless of whether and exposure was long or short, those administered at the end of the
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exercise regiment would result in higher breath concentrations.  In general that trend is seen in
all four subjects, that is either the LE or the SE always yield more CFC in the exhaled breath..
With the four scenarios, there are no obvious or consistent patterns from subject to subject; in
two cases the LE trials appear greater than the other three, in 2 other cases, the SE trials yielded
higher concentrations.  Furthermore, in the two cases where the SE tests were the highest, the LE
tests were the lowest.
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Chapter 7
        Recommendations
The different exposure scenarios designed in this study were intended to represent the
possible ways in which leaks might occur during respirator tests that utilize CFC-113 as a
challenge agent.  The statistical analysis has shown that the onset, duration, and magnitude of the
leaks should not bias the exhaled breath sample CFC-113 concentration in respirator studies,
with the exception of the SE and LE scenarios for two cases.  The statistical analysis supports the
concept that the end-exhaled breath sample is representative of the dose that the wearer was
exposed to rather than a factor of the leak profile.  The great deal of variation in the test
repetitions suggests that errors occurred in the experiment.  It is possible that the variation in this
study masked many of the trends.  The variation should be pinpointed and eliminated from
further studies.
Some variation may be attributed to the GC calibration coefficient or during IR
calibration.  In the future it is recommended that anomalous calibration coefficients be examined
carefully and perhaps recalculated.  I recommend that these instruments be calibrated weekly.
Some variability may be reduced if the sample collection times were delayed for 10 minutes or if
only the 35-minute post-exposure samples were considered.
Since a great deal of the variation may have been caused by physiological factors, the
significance level of future research should be raised to 90% (α = 0.1) and, if practical, the
number of replications should be enlarged to increase the strength of the Duncan test.
Furthermore, the statistical analysis should include the Least Significant Difference Method and
the Tukey Test.
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Finally, future research might want to consider replacing the CFC-113 Delivery System
with a modified anesthesiology machine. An anesthesiology machine might ensure more
consistent and accurate CFC-113 administration because it would provide a closed system, with
precise dosing, and a finely regulated and controlled flow rate.   Such a machine could be
modified easily for CFC-113 administration, and the mask could be probe to allow samples to be
drawn and analyzed by the IR.
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Appendix A
Breath Sample Data from the ECD
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Original Data
ECD AREA VALUES ECD
Subject Data Phase Test 25 min. 30 min. 35 min. CAL. CO.
1 3/26/98 1 LB PROB 71106 89835 186508
1 2/13/98 1 LB 67845 65800 62146 97802
1 4/9/98 1 LB 106545 115829 117757 186508
1 2/6/98 1 LE 69123 60744 72084 97802
1 2/27/98 1 LE 45814 39535 37818 99910
1 2/2/98 1 LE 94752 84776 87319 97802
1 2/24/98 1 SB 59828 55982 50071 99910
1 2/20/98 1 SB 65487 51064 72024 97802
1 3/19/98 1 SB 45252 41165 38339 80211
1 3/27/98 1 SE 124739 106805 95027 186508
1 3/31/98 1 SE 120465 120206 116111 186508
1 3/5/98 1 SE 69720 57970 70673 99910
3 2/6/98 2 BEG 186788 180553 167708 97802
3 2/20/98 2 BEG 137387 152019 150047 97802
3 3/27/98 2 BEG 125532 119001 149683 186508
3 2/13/98 2 END 83424 72545 85211 97802
3 2/27/98 2 END 152947 153299 152255 99910
3 3/20/98 2 END 209217 169518 144501 80211
4 2/6/98 3 CON 192190 164682 156955 97802
4 1/30/98 3 CON 150599 140485 101142 97802
4 2/27/98 3 CON 133673 149475 90122 99910
4 2/20/98 3 INT 181973 146039 144742 97802
4 2/13/98 3 INT 136458 79130 87906 97802
4 1/23/98 3 INT 88809 105581 115113 97802
5 2/10/98 1 LB 72854 98882 87769 97802
5 2/27/98 1 LB 43935 38910 40184 99910
5 1/28/98 1 LB 38422 38918 44061 97802
5 1/30/98 1 LE 40416 38507 36983 97802
5 2/13/98 1 LE 51243 51858 53551 97802
5 1/23/98 1 LE 35428 36759 29233 97802
5 2/6/98 1 SB 79575 66117 64613 97802
5 2/17/98 1 SB 89741 95346 73278 97802
5 3/3/98 1 SB 65907 62913 53993 99910
5 2/3/98 1 SE 79874 72872 73296 97802
5 2/24/98 1 SE 78989 63814 64092 99910
5 3/17/98 1 SE 76273 69613 68316 80211
8 1/30/98 1 LB 42045 40741 PROB 97802
8 2/19/98 1 LB 46386 56059 64658 97802
8 2/17/98 1 LB 56647 61667 68258 97802
8 2/12/98 1 LE 62914 61132 67331 97802
8 3/19/98 1 LE 77575 75147 83538 80211
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ECD AREA VALUES ECD
Subject Data Phase Test 25 min. 30 min. 35 min. CAL. CO.
8 2/26/98 1 LE 77778 56510 56530 99910
8 2/24/98 1 SB 62898 63962 68856 99910
8 2/5/98 1 SB 82639 82850 77336 97802
8 4/1/98 1 SB 119985 105091 120233 186508
8 2/10/98 1 SE 125420 120604 108463 97802
8 3/3/98 1 SE 75662 60221 79376 99910
8 3/26/98 1 SE 130729 144274 118271 186508
10 2/10/98 3 CON 153102 133093 161690 97802
10 2/24/98 3 CON 100287 82817 78938 99910
10 1/28/98 3 CON 117823 113012 77130 97802
10 3/17/98 3 INT 73589 83665 65973 80211
10 2/3/98 3 INT 146597 162078 136108 97802
10 3/24/98 3 INT 109173 51395 69282 186508
16 2/2/98 2 BEG 234829 194486 156982 97802
16 3/3/98 2 BEG 121669 120938 102333 99910
16 2/23/98 2 BEG 90346 103405 92179 99910
16 3/17/98 2 END 173858 158833 137291 80211
16 3/31/98 2 END 264555 217504 212430 186508
16 3/20/98 2 END 248798 200481 184056 80211
19 4/2/98 3 CON 163365 154023 182170 186508
19 2/5/98 3 CON 199102 163545 131747 97802
19 2/12/98 3 CON 124307 117432 96200 97802
19 3/5/98 3 INT 117229 100860 82628 99910
19 2/26/98 3 INT 136255 98342 95872 99910
19 2/19/98 3 INT 76814 68120 57812 97802
22 2/5/98 2 BEG 153003 111426 123172 97802
22 2/26/98 2 BEG 167616 169202 133388 99910
22 3/5/98 2 BEG 219124 175747 148304 99910
22 1/29/98 2 END 230660 203104 171566 97802
22 2/19/98 2 END 167259 121219 87196 97802
22 2/12/98 2 END 155726 133323 110188 97802
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ECD AREA VALUES ECD
Subject Data Phase Test 25 min. 30 min. 35 min. CAL. CO.
26 2/26/98 2 BEG 141066 134187 121553 99910
26 2/13/98 2 BEG 91983 85291 80631 97802
26 1/23/98 2 BEG 95786 101496 70174 97802
26 1/29/98 2 END 137058 143059 PROB 97802
26 3/19/98 2 END 177338 157070 166358 80211
26 2/3/98 2 END 264705 180313 138063 97802
29 1/30/98 3 CON 167884 162435 152983 97802
29 2/13/98 3 CON 96916 114700 91672 97802
29 2/6/98 3 CON 226852 223722 201145 97802
29 2/20/98 3 INT 160838 161480 127739 97802
29 3/20/98 3 INT 257392 224576 238790 80211
29 2/27/98 3 INT 170259 136892 138032 99910
45 2/19/98 3 LB 73006 69213 72793 97802
45 3/27/98 1 LB 112071 118715 127695 186508
45 3/20/98 1 LB 98264 87729 124328 80211
45 4/16/98 1 LE 121859 112279 123809 186508
45 4/10/98 1 LE 101222 95376 95887 186508
45 3/26/98 1 LE 71297 62020 69502 186508
45 4/14/98 1 SB 124737 124587 123573 186508
45 3/31/98 1 SB 125746 138244 132898 186508
45 2/12/98 1 SB 68453 65340 70041 97802
45 4/17/98 1 SE 164926 153876 166846 186508
45 2/5/98 1 SE 125825 104876 81035 97802
45 4/15/98 1 SE 163333 133772 169347 186508
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Appendix B
Photos of CFC-113 Delivery System and Chamber
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Figure B1
CFC-113 Delivery System
76
Figure B2
Subject Donning CFC-113 Delivery System
R
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Figure B3
Subject in a Charged Chamber
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Appendix C
Calibration Graphs
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Appendix D
SAS Results
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Comp=LBLESBSE Subject =1
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 1
TEST 4 LB LE SB SE
Number of observations in by group = 12
General Linear Models Procedure
Dependent Variable; CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 3 0.02380000 0.00793333 0.36 0.7847
Error 8 0.17706667 0.02213333
Corrected Total 11 0.20086667
R-Squared C.V. Root MSE CONC Mean
0.118487 24.52298 0.14877276 0.60666667
Source DF Type I SS Mean Square F Value Pr > F
TEST 3 0.02380000 0.00793333 0.36 0.7847
Source DF Type III SS Mean Square F Value Pr > F
TEST 3 0.02380000 0.00793333 0.36 0.7847
83
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 8 MSE= 0.022133
Number of Means 2 3 4
Critical Range .2801 .2919 .2985
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 0.6700 3 LE
A 0.6267 3 SE
A 0.5700 3 SB
A 0.5600 3 LB
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Comp=LBLESBSE Subject =45
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 45
TEST 4 LB LE SB SE
Number of observations in by group = 12
General Linear Models Procedure
Dependent Variable; CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 3 0.33115833 0.11038611 2.77 0.1106
Error 8 0.33115833 0.03981667
Corrected Total 11 0.64969167
R-Squared C.V. Root MSE CONC Mean
0.509716 6.57596 0.19954114 0.75083333
Source DF Type I SS Mean Square F Value Pr > F
TEST 3 0.33115833 0.11038611 2.77 0.1106
Source DF Type III SS Mean Square F Value Pr > F
TEST 3 0.33115833 0.11038611 2.77 0.1106
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Subject = 45
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 8 MSE= 0.039817
Number of Means 2 3 4
Critical Range .3757 .3915 .4004
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 0.9200 3 SE
B A 0.8867 3 LB
B A 0.6900 3 SB
B 0.5067 3 LE
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Comp=LBLESBSE Subject =5
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 5
TEST 4 LB LE SB SE
Number of observations in by group = 12
General Linear Models Procedure
Dependent Variable; CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 3 0.24070000 0.08023333 2.90 0.1019
Error 8 0.22166667 0.02770833
Corrected Total 11 0.46236667
R-Squared C.V. Root MSE CONC Mean
0.520583 26.49202 0.16645820 0.62833333
Source DF Type I SS Mean Square F Value Pr > F
TEST 3 0.24070000 0.08023333 2.90 0.1019
Source DF Type III SS Mean Square F Value Pr > F
TEST 3 0.24070000 0.08023333 2.90 0.1019
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Subject = 5
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 8 MSE= 0.027708
Number of Means 2 3 4
Critical Range .3134 .3266 .3340
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 0.7833 3 SE
B A 0.7367 3 SB
B A 0.5667 3 LB
B 0.4267 3 LE
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Comp=LBLESBSE Subject =8
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 8
TEST 4 LB LE SB SE
Number of observations in by group = 12
General Linear Models Procedure
Dependent Variable; CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 3 0.19070000 0.06356667 1.66 0.2522
Error 8 0.30680000 0.03835000
Corrected Total 11 0.49750000
R-Squared C.V. Root MSE CONC Mean
0.383317 27.38903 0.19583156 0.71500000
Source DF Type I SS Mean Square F Value Pr > F
TEST 3 0.19070000 0.06356667 1.66 0.2522
Source DF Type III SS Mean Square F Value Pr > F
TEST 3 0.19070000 0.06356667 1.66 0.2522
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Subject = 8
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 8 MSE= 0.03835
Number of Means 2 3 4
Critical Range .3687 .3842 .3929
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 0.8767 3 SE
A 0.7567 3 LE
A 0.7000 3 SB
A 0.5267 3 LB
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Comp=begend Subject =16
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 16
TEST 2 BEG END
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.49306667 0.49306667 1.24 0.3275
Error 4 1.58786667 0.39696667
Corrected Total 5 2.08093333
R-Squared C.V. Root MSE CONC Mean
0.236945 38.10804 0.63005291 1.65333333
Source DF Type I SS Mean Square F Value Pr > F
TEST 3 0.49306667 0.49306667 1.24 0.3275
Source DF Type III SS Mean Square F Value Pr > F
TEST 3 0.49306667 0.49306667 1.24 0.3275
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Subject = 16
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.396967
Number of Means 2
Critical Range 1.428
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.9400 3 END
A 1.3667 3 BEG
92
Comp=begend Subject =22
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 22
TEST 2 BEG END
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.00000000 0.00000000 0.00 1.0000
Error 4 0.48833333 0.12208333
Corrected Total 5 0.48833333
R-Squared C.V. Root MSE CONC Mean
0.00000 22.30240 0.34940425 1.56666667
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.00000000 0.00000000 0.00 1.0000
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.00000000 0.00000000 0.00 1.0000
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Subject = 22
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.122083
Number of Means 2
Critical Range .7921
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.5667 3 BEG
A 1.5667 3 END
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Comp=begend Subject =26
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 26
TEST 2 BEG END
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.82140000 0.82140000 6.25 0.0667
Error 4 0.52533333 0.13133333
Corrected Total 5 1.34673333
R-Squared C.V. Root MSE CONC Mean
0.609920 25.76299 0.36239941 1.40666667
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.82140000 0.82140000 6.25 0.0667
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.82140000 0.82140000 6.25 0.0667
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Subject = 26
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.131333
Number of Means 2
Critical Range .8215
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.7767 3 END
A 1.0367 3 BEG
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Comp=begend Subject =3
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 3
TEST 2 BEG END
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.04166667 0.04166667 0.11 0.7615
Error 4 1.57766667 0.39441667
Corrected Total 5 1.61933333
R-Squared C.V. Root MSE CONC Mean
0.025731 44.12361 0.62802601 1.423333333
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.04166667 0.04166667 0.11 0.7615
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.04166667 0.04166667 0.11 0.7615
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Subject = 3
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.394417
Number of Means 2
Critical Range 1.424
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.5067 3 END
A 1.3400 3 BEG
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Comp=CONINT Subject =10
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 10
TEST 2 CON INT
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.05801667 0.05801667 0.27 0.6289
Error 4 0.84966667 0.21241667
Corrected Total 5 0.90768333
R-Squared C.V. Root MSE CONC Mean
0.063917 43.82442 0.46088683 1.05166667
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.05801667 0.05801667 0.27 0.6289
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.05801667 0.05801667 0.27 0.6289
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Subject = 10
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.212417
Number of Means 2
Critical Range 1.045
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.1500 3 CON
A 0.9533 3 INT
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Comp=CONINT Subject =19
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 19
TEST 2 CON INT
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.14726667 0.14726667 1.39 0.3041
Error 4 0.42446667 0.10611667
Corrected Total 5 0.57173333
R-Squared C.V. Root MSE CONC Mean
0.257579 29.97750 0.32575553 1.08666667
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.14726667 0.14726667 1.39 0.3041
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.14726667 0.14726667 1.39 0.3041
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Subject = 19
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.10611667
Number of Means 2
Critical Range 1.045
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.2433 3 CON
A 0.9300 3 INT
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Comp=CONINT Subject =29
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 29
TEST 2 CON INT
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.20906667 0.20906667 0.38 0.5700
Error 4 2.18933333 0.54733333
Corrected Total 5 2.39840000
R-Squared C.V. Root MSE CONC Mean
0.087169 40.64944 0.73981980 1.82000000
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.20906667 0.20906667 0.38 0.5700
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.20906667 0.20906667 0.38 0.5700
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Subject = 29
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.547333
Number of Means 2
Critical Range 1.677
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 2.0067 3 INT
A 1.6333 3 CON
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Comp=CONINT Subject =4
General Linear Models Procedure
Class Level Information
Class Levels Values
SUBJECT 1 4
TEST 2 CON INT
Number of observations in by group = 6
General Linear Models Procedure
Dependent Variable: CONC
Source DF Sum of Squares Mean Square F Value Pr > F
Model 1 0.07041667 0.07041667 0.78 0.4257
Error 4 0.35886667 0.08971667
Corrected Total 5 0.42928333
R-Squared C.V. Root MSE CONC Mean
0.164033 22.38063 0.29952741 1.33833333
Source DF Type I SS Mean Square F Value Pr > F
TEST 1 0.07041667 0.07041667 0.78 0.4257
Source DF Type III SS Mean Square F Value Pr > F
TEST 1 0.07041667 0.07041667 0.78 0.4257
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Subject = 4
General Linear Models Procedure
Duncan's Multiple Range Test for variable: CONC
Note: This test controls the type I comparisonwise error rate,  not the experimentwise error rate
Alpha= 0.05 df= 4 MSE= 0.089717
Number of Means 2
Critical Range 0.6790
Means with the same letter are not significantly different.
Duncan Grouping Mean N TEST
A 1.4467 3 CON
A 1.2300 3 INT
